MA33386B1 - Derives d'imidazole en tant qu'antagonistes de mglur5 - Google Patents
Derives d'imidazole en tant qu'antagonistes de mglur5Info
- Publication number
- MA33386B1 MA33386B1 MA34494A MA34494A MA33386B1 MA 33386 B1 MA33386 B1 MA 33386B1 MA 34494 A MA34494 A MA 34494A MA 34494 A MA34494 A MA 34494A MA 33386 B1 MA33386 B1 MA 33386B1
- Authority
- MA
- Morocco
- Prior art keywords
- lower alkyl
- hydroxyalkyl
- represent independently
- imidazole derivatives
- iib
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION PORTE SUR DES DÉRIVÉS D'IMIDAZOLE DE LA FORMULE GÉNÉRALE (I) DANS LAQUELLE R1 SIGNIFIE HALOGÈNE, ALKYLE INFÉRIEUR OU ALCOXY INFÉRIEUR; R2 SIGNIFIE ALKYLE INFÉRIEUR, HYDROXYALKYLE INFÉRIEUR OU ALCOXYALKYLE INFÉRIEUR; R3 SIGNIFIE HYDROGÈNE, ALKYLE INFÉRIEUR, HYDROXYALKYLE OU ALCOXYALKYLE INFÉRIEUR; Q SIGNIFIE SOIT ?N= SOIT ?CH=; R4 EST UN GROUPE DE FORMULE IIA OU IIB (FORMULE IIA ET IIB) DANS LESQUELLES X, Y ET Z REPRÉSENTENT INDÉPENDAMMENT ?CH= OU ?N= ET OÙ SEUL L'UN DE X OU Y PEUT ÊTRE UN ATOME D'AZOTE; R5 ET R6 REPRÉSENTENT INDÉPENDAMMENT HYDROGÈNE, ALKYLE INFÉRIEUR, HYDROXYALKYLE INFÉRIEUR, ALCOXYALKYLE INFÉRIEUR, (CH2)M-(CO)O-ALKYLE INFÉRIEUR, (CH2)M-S(O)2-ALKYLE INFÉRIEUR, (CH2)M-C(O)-NR'R" ET OÙ M = 0-3 ET R' ET R" REPRÉSENTENT INDÉPENDAMMENT HYDROGÈNE OU ALKYLE INFÉRIEUR; AINSI QUE SUR DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CEUX-CI. IL A MAINTENANT ÉTÉ TROUVÉ DE FAÇON SURPRENANTE QUE LES COMPOSÉS DE FORMULE GÉNÉRALE I SONT DES ANTAGONISTES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE. ILS PEUVENT ÊTRE UTILISÉS DANS LE TRAITEMENT OU LA PRÉVENTION DE TROUBLES À MÉDIATION PAR LE RÉCEPTEUR DE MGLUR5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09165780 | 2009-07-17 | ||
| PCT/EP2010/060097 WO2011006910A1 (fr) | 2009-07-17 | 2010-07-14 | Dérivés d'imidazole en tant qu'antagonistes de mglur5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33386B1 true MA33386B1 (fr) | 2012-06-01 |
Family
ID=42358156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34494A MA33386B1 (fr) | 2009-07-17 | 2010-07-14 | Derives d'imidazole en tant qu'antagonistes de mglur5 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8334287B2 (fr) |
| EP (1) | EP2456765B1 (fr) |
| JP (1) | JP5667182B2 (fr) |
| KR (1) | KR101431347B1 (fr) |
| CN (1) | CN102471309B (fr) |
| AR (1) | AR077481A1 (fr) |
| AU (1) | AU2010272585B2 (fr) |
| BR (1) | BR112012001092A2 (fr) |
| CA (1) | CA2765921C (fr) |
| CL (1) | CL2012000102A1 (fr) |
| CO (1) | CO6400142A2 (fr) |
| CR (1) | CR20110659A (fr) |
| CY (1) | CY1114186T1 (fr) |
| DK (1) | DK2456765T3 (fr) |
| EC (1) | ECSP12011611A (fr) |
| ES (1) | ES2411467T3 (fr) |
| HK (1) | HK1169397A1 (fr) |
| HR (1) | HRP20130657T1 (fr) |
| IL (1) | IL216746A (fr) |
| MA (1) | MA33386B1 (fr) |
| MX (1) | MX2012000814A (fr) |
| MY (1) | MY156878A (fr) |
| NZ (1) | NZ596810A (fr) |
| PE (1) | PE20120397A1 (fr) |
| PL (1) | PL2456765T3 (fr) |
| PT (1) | PT2456765E (fr) |
| RS (1) | RS52901B (fr) |
| RU (1) | RU2527106C2 (fr) |
| SG (1) | SG178052A1 (fr) |
| SI (1) | SI2456765T1 (fr) |
| TW (1) | TWI423964B (fr) |
| UA (1) | UA107086C2 (fr) |
| WO (1) | WO2011006910A1 (fr) |
| ZA (1) | ZA201109451B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| US20170173008A1 (en) * | 2014-03-19 | 2017-06-22 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965583A (en) * | 1997-04-24 | 1999-10-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory disease |
| KR100515549B1 (ko) | 2000-12-04 | 2005-09-20 | 에프. 호프만-라 로슈 아게 | 글루타메이트 수용체 길항제로서의 페닐에테닐 또는페닐에티닐 유도체 |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| TWI292318B (en) * | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| EP1670784B1 (fr) * | 2003-06-12 | 2011-01-12 | F. Hoffmann-La Roche AG | Derives d'imidazoles substitues par heteroaryle, utilises comme antagonistes du recepteur de glutamate |
| US7452909B2 (en) * | 2003-09-04 | 2008-11-18 | Hoffman-La Roche Inc. | Imidazole derivatives |
| PL1756086T3 (pl) * | 2004-06-01 | 2008-11-28 | Hoffmann La Roche | Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5 |
| BRPI0511678A (pt) * | 2004-06-01 | 2008-01-08 | Hoffmann La Roche | piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5 |
| EP2578216A1 (fr) | 2006-11-22 | 2013-04-10 | Seaside Therapeutics, Inc. | Procédés de traitement du syndrome de l'X fragile |
-
2010
- 2010-07-09 US US12/833,017 patent/US8334287B2/en active Active
- 2010-07-14 PT PT107301921T patent/PT2456765E/pt unknown
- 2010-07-14 CN CN201080031886.6A patent/CN102471309B/zh active Active
- 2010-07-14 SG SG2012003661A patent/SG178052A1/en unknown
- 2010-07-14 SI SI201030209T patent/SI2456765T1/sl unknown
- 2010-07-14 CA CA2765921A patent/CA2765921C/fr not_active Expired - Fee Related
- 2010-07-14 RU RU2012104399/04A patent/RU2527106C2/ru not_active IP Right Cessation
- 2010-07-14 KR KR1020127004121A patent/KR101431347B1/ko active IP Right Grant
- 2010-07-14 PE PE2012000035A patent/PE20120397A1/es not_active Application Discontinuation
- 2010-07-14 AU AU2010272585A patent/AU2010272585B2/en not_active Ceased
- 2010-07-14 TW TW099123206A patent/TWI423964B/zh not_active IP Right Cessation
- 2010-07-14 UA UAA201201027A patent/UA107086C2/ru unknown
- 2010-07-14 EP EP10730192.1A patent/EP2456765B1/fr active Active
- 2010-07-14 RS RS20130331A patent/RS52901B/en unknown
- 2010-07-14 DK DK10730192.1T patent/DK2456765T3/da active
- 2010-07-14 WO PCT/EP2010/060097 patent/WO2011006910A1/fr active Application Filing
- 2010-07-14 MA MA34494A patent/MA33386B1/fr unknown
- 2010-07-14 BR BR112012001092-1A patent/BR112012001092A2/pt not_active Application Discontinuation
- 2010-07-14 JP JP2012520013A patent/JP5667182B2/ja active Active
- 2010-07-14 MY MYPI2012000151A patent/MY156878A/en unknown
- 2010-07-14 MX MX2012000814A patent/MX2012000814A/es active IP Right Grant
- 2010-07-14 ES ES10730192T patent/ES2411467T3/es active Active
- 2010-07-14 NZ NZ596810A patent/NZ596810A/en not_active IP Right Cessation
- 2010-07-14 PL PL10730192T patent/PL2456765T3/pl unknown
- 2010-07-15 AR ARP100102580A patent/AR077481A1/es unknown
-
2011
- 2011-11-29 CO CO11164352A patent/CO6400142A2/es active IP Right Grant
- 2011-12-01 IL IL216746A patent/IL216746A/en not_active IP Right Cessation
- 2011-12-08 CR CR20110659A patent/CR20110659A/es unknown
- 2011-12-21 ZA ZA2011/09451A patent/ZA201109451B/en unknown
-
2012
- 2012-01-13 CL CL2012000102A patent/CL2012000102A1/es unknown
- 2012-01-17 EC EC2012011611A patent/ECSP12011611A/es unknown
- 2012-10-12 HK HK12110080.6A patent/HK1169397A1/xx unknown
-
2013
- 2013-07-10 HR HRP20130657AT patent/HRP20130657T1/hr unknown
- 2013-07-22 CY CY20131100614T patent/CY1114186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2010000248A1 (fr) | Derives d'indolinone et procede pour leur fabrication | |
| MA30428B1 (fr) | Derives de dihydropyrazolopyrimidinones | |
| MA30355B1 (fr) | Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3 | |
| MA31865B1 (fr) | Dérivés isoxazolo-pyridine | |
| MA26996A1 (fr) | Derives de glutaramide a substituant n-phenpropylcyclopentyle, servant d'inhibiteurs de nep pour un trouble d'eveil sexuel feminin | |
| TNSN08337A1 (fr) | Piperidinoylpyrrolidines agonistes du recepteur de melanocortine de type 4 | |
| TNSN05309A1 (fr) | Derives d'imidazole utilises comme antagonistes du recepteur du glutamate | |
| MA30289B1 (fr) | Dérivés d'amines | |
| MX2007014403A (es) | Derivados de fenil-3-{(3-(1h-pirrol-2-il)-[1,2,4]oxadiazol-5-il]pi peridin-1-il}-metanona y compuestos relacionados como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. | |
| MA28432B1 (fr) | Antagonistes du recepteur de la chimiokine | |
| HUP9902136A2 (hu) | Szubsztituált ciklusos aminosavszármazékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| MA33802B1 (fr) | Dérivés d'éthynyle | |
| TNSN06369A1 (fr) | Derives de tetrahydronaphtyridine utiles comme ligands du recepteur d'histamine h3 | |
| TN2009000112A1 (fr) | Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques | |
| WO2020047035A1 (fr) | Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules | |
| MXPA05010824A (es) | Compuestos biciclicos como antagonistas del receptor nr2b. | |
| EA200701583A1 (ru) | Гетероциклические тетрациклические производные гидрофурана в качестве ингибиторов 5нт2 в терапии расстройств цнс | |
| MX2007004199A (es) | Derivados de indol sustituidos con 5-sulfonil-1-piperidinil como antagonistas del receptor 5-ht6 para el tratamiento de trastornos del cns. | |
| MA45888A1 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
| MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
| TN2009000470A1 (fr) | Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2 | |
| MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
| MA27795A1 (fr) | Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant |